Autres langues aTyr Pharma, Inc.

Actions

LIFE

US0021202025

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
1,61 ^USD	+0,62 %		+2,55 %	+14,18 %

02/05	ATyr Pharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
15/03	ATYR PHARMA, INC. : Opinion positive de RBC Capital Markets	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atyr Pharma: Q1 Earnings Snapshot	02/05
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	02/05
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update	02/05
ATyr Pharma to Participate in April Investor Conferences	01/04
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Atyr Pharma: Q4 Earnings Snapshot	14/03
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	14/03
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	28/02
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	21/02
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	21/02
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	29/01
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor	18/01
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023	13/11
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Atyr Pharma: Q3 Earnings Snapshot	09/11
ATyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update	09/11
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000	09/11
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD	01/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues aTyr Pharma, Inc.

Actions

LIFE

US0021202025

Autres langues

Filtres